| Literature DB >> 29336370 |
Ying Bai1, Xu-Bo Shi1, Yu-Qiong Zhang1, Yue-Li Wang2, Xin-Yao Liu1, María Asunción Esteve-Pastor3.
Abstract
BACKGROUND: Matrix metalloproteinase (MMP)-2 plays an important role in the remodeling of left ventricles (LVs) and right ventricles (RVs). We investigated the differences of MMP-2 expression between LV and RV in response to nandrolone decanoate (ND), swimming training (ST), and combined ND and ST (NS) in mice, based on their structural, functional, and biochemical characteristics.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29336370 PMCID: PMC5776852 DOI: 10.4103/0366-6999.222330
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Comparison of Baseline and 8-week body weight within and between groups
| Group | Number | Baseline | 8 weeks | Difference between baseline and 8 weeks | ||
|---|---|---|---|---|---|---|
| Control | 7 | 21.86 ± 0.34 | 29.38 ± 0.81 | 7.53 ± 1.14 | 6.61 | 0.001 |
| ND | 6 | 21.67 ± 0.33 | 31.72 ± 0.76* | 10.05 ± 0.71 | 14.10 | <0.001 |
| ST | 8 | 21.63 ± 0.26 | 29.24 ± 0.71 | 7.62 ± 0.69 | 11.00 | <0.001 |
| NS | 7 | 21.71 ± 0.42 | 27.82 ± 0.51 | 6.11 ± 0.62 | 9.92 | <0.001 |
No significant difference between each other at baseline; *P<0.05 from the control, ST and NS groups at 8 weeks. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training.
Cardiac parameters of four different treatment groups at 8 weeks
| Groups | BW (g) | HW (g) | LVW (g) | RVW (g) | HW/BW (mg/g) | LVW/BW (mg/g) | RVW/BW (mg/g) |
|---|---|---|---|---|---|---|---|
| Control ( | 29.386 ± 0.813 | 0.174 ± 0.009 | 0.102 ± 0.007 | 0.023 ± 0.004 | 0.595 ± 0.027† | 0.351 ± 0.019 | 0.080 ± 0.012 |
| ND ( | 31.716 ± 0.756* | 0.188 ± 0.006 | 0.097 ± 0.002 | 0.026 ± 0.004 | 0.594 ± 0.022† | 0.315 ± 0.001 | 0.084 ± 0.010 |
| ST ( | 29.244 ± 0.710 | 0.194 ± 0.008 | 0.103 ± 0.007 | 0.028 ± 0.001 | 0.668 ± 0.035 | 0.358 ± 0.030 | 0.096 ± 0.001 |
| NS ( | 27.824 ± 0.508 | 0.198 ± 0.008 | 0.106 ± 0.007 | 0.027 ± 0.003 | 0.710 ± 0.024 | 0.379 ± 0.014 | 0.095 ± 0.008 |
| 4.73 | 1.59 | 0.28 | 0.39 | 3.83 | 1.45 | 0.74 | |
| 0.010 | 0.219 | 0.841 | 0.762 | 0.023 | 0.278 | 0.547 | |
*P<0.05 from the control, ST, and NS groups; †P<0.05 from NS group. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; BW: Body weight; HW: Heart weight; LVW: Left ventricular weight; RVW: Right ventricular weight.
Echocardiographic parameters in four different treatment groups at 8 weeks
| Groups | LV dimension and function | RV dimension and function | |||||
|---|---|---|---|---|---|---|---|
| LVDd/BW (cm/g) | LVDs/BW (cm/g) | E/A ratio | RVD/BW (cm/g) | E-velocity§ (cm/s) | E-DT (s) | E/A ratio | |
| Control ( | 1.140 ± 0.040 | 0.630 ± 0.060 | 2.250 ± 0.036 | 0.530 ± 0.058 | 30.000 ± 0.580 | 0.130 ± 0.006 | 2.000 ± 0.039 |
| ND ( | 1.380 ± 0.070 | 0.880 ± 0.080 | 2.390 ± 0.052 | 0.620 ± 0.014† | 55.000 ± 15.000* | 0.160 ± 0.010 | 4.500 ± 2.500 |
| ST ( | 1.390 ± 0.140 | 1.020 ± 0.140* | 2.490 ± 0.391 | 0.570 ± 0.017 | 33.000 ± 3.330‡ | 0.140 ± 0.010 | 1.560 ± 0.560 |
| NS ( | 1.250 ± 0.050 | 0.830 ± 0.060 | 1.790 ± 0.1550 | 0.580 ± 0.005* | 59.250 ± 3.590* | 0.280 ± 0.025† | 3.720 ± 0.610 |
| 1.18 | 2.22 | 1.43 | 7.12 | 8.30 | 15.31 | 2.23 | |
| 0.359 | 0.139 | 0.283 | 0.005 | 0.008 | 0.001 | 0.163 | |
*P<0.05 compared with control group; †P<0.05 compared with the other three groups; ‡P<0.05 compared with ND and NS groups; §ND (n = 2), and ST (n = 3) for calculation of E-velocity. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; LV: Left ventricle; RV: Right ventricle; BW: Body weight; LVDd: Left ventricular end-diastolic dimension; LVDs: Left ventricular end-systolic dimension; RVD: Right ventricular end-diastolic dimension; E-DT: E deceleration time.
Figure 1Diagrams of mouse echocardiography at the papillary level of short-axis view in four different treatment groups at 8 weeks. RVD in the ND group was larger compared to the other three groups (arrows). (a) Control group; (b) ND group; (c) ST group; (d) NS group. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; RV: Right ventricle; RVD: Right ventricular end-diastolic dimension.
Figure 2Fibrosis in four different treatment groups of left (a-d) and right ventricles (e-h) of the mice at 8 weeks using Van-Gieson staining. Fibrosis (arrows) in left ventricles of the control (a), ND (b), ST (c), and NS (d) groups; fibrosis (arrows) in right ventricles of the control (e), ND (f), ST (g), and NS (h) groups. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; LV: Left ventricle; RV: Right ventricle.
Figure 3Relative levels of fibrosis in left and right ventricles in four different treatment groups at 8 weeks. *P < 0.05 compared to the ND group of the left ventricle; †P < 0.05 compared to the corresponding control group of the left ventricle; ‡P < 0.05 compared to the corresponding control group of the right ventricle. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; LV: Left ventricle; RV: Right ventricle.
Figure 4Different MMP-2 expression in left and right ventricles in four different treatment groups at 8 weeks. *P < 0.05 compared to the corresponding treatment group of left ventricle; †P < 0.05 compared to the corresponding control group of left ventricle; ‡P < 0.05 compared to the corresponding control group of right ventricle. ND: Nandrolone decanoate; ST: Swimming training; NS: Combined nandrolone decanoate and swimming training; LV: Left ventricle; RV: Right ventricle; LV-C: Left ventricle of the control group; RV-C: Right ventricle of the control group; MMP-2: Matrix metalloproteinases-2; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.